SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (192)5/15/2002 10:55:13 AM
From: scaram(o)uche  Read Replies (1) of 598
 
During the quarter ended March 31, 2002, we disclosed plans to pursue phase 3 clinical studies with T67 for the treatment of hepatocellular carcinoma, or primary liver cancer. T67, discovered and developed at Tularik, is an anti-cancer drug candidate that binds irreversibly to tubulin. T67 has shown activity in phase 1 and phase 2 trials for the treatment of hepatocellular carcinoma, a refractory malignancy for which there are no approved systemic chemotherapeutic agents. T67 also demonstrated activity in the phase 2 brain cancer trial, but did not demonstrate activity in the other indications tested. Data from the phase 2 hepatocellular carcinoma trials with T67 will be available at the American Society of Clinical Oncology (ASCO) meeting in May 2002.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News